Compare Salesforce Inc (CRM) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs IDEXX Laboratories, Inc. — how do they compare? Salesforce Inc trades at $167.45 (market cap $137.23B), while IDEXX Laboratories, Inc. trades at $565.58 (market cap $42.65B). The key difference: Salesforce Inc is far larger — about 3.2× IDEXX Laboratories, Inc.'s market cap, and Salesforce Inc pays a 1.05% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| CRM | IDXX | |
|---|---|---|
Market Cap | $137.23B | $42.65B |
Sector | Technology | Health |
52-Week High | $270.25 | $766.68 |
52-Week Low | $150.12 | $514.61 |
Enterprise Value | $167.28B | $43.56B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $167.70, down 2.06% amid broader software sector weakness. The stock shows strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs $3.13 expected) and robust profitability (77.6% gross margin). Technical indicators are neutral with support at $165 and resistance at $171. Recent AI-driven growth initiatives, including Agentforce reaching $2.9B ARR, position the company for continued expansion despite current market pressures.
CRM presents a compelling long-term opportunity with 76.8% analyst buy ratings and a $235.90 consensus target (40% upside). Risks include sector volatility from AI competition and macroeconomic headwinds, but strong cash flow generation ($13.1B operating cash flow in 2025) and market leadership support the bullish case for patient investors.
IDXX trades at $564.09, up 0.09% with neutral technical signals. The stock shows strong fundamentals with revenue growth to $4.3B in 2025 and consistent earnings beats. Analyst consensus is bullish (59% Buy) with improving cash flow trends. Recent news highlights AI integration in medical devices and upcoming Q2 2026 earnings.
Outlook remains positive driven by innovation and market leadership in pet healthcare. Risks include high valuation multiples and competitive pressures. Institutional sentiment supports growth, but investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
